Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T18:58:08.653Z.
Consensus retrieved: 2026-10-06T15:02:12.718Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T18:58:08.653Z.
Quote observation: 2026-10-06T18:55:19.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 6b7402e8e4aad00529a5dc64304a2ec9485b3d7feb734bca750ca78a67bf3000
Forward PE Ratio (N/A) = Dated Quote Price ($2.71) / Consensus Forward EPS ($-0.46)
FORWARD PE RATIO
N/A
Pacific Biosciences of California, Inc.
Market Cap
$843.28M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Pacific Biosciences of California, Inc. (PACB) | $843.28M | N/A |
| QuidelOrtho Corporation (QDEL)vs › | $843.86M | 16.02 |
| SpyGlass Pharma, Inc. Common Stock (SGP)vs › | $842.59M | N/A |
| Beta Bionics, Inc. (BBNX)vs › | $841.31M | N/A |
| Alumis Inc. (ALMS)vs › | $839.96M | N/A |
| Monte Rosa Therapeutics, Inc. (GLUE)vs › | $834.27M | N/A |
| SI-BONE, Inc. (SIBN)vs › | $857.03M | N/A |
| SL Science Holding Ltd (SLBT)vs › | $863.57M | N/A |
| Rigel Pharmaceuticals, Inc. (RIGL)vs › | $863.85M | 13.61 |
| Ardelyx, Inc. (ARDX)vs › | $816.73M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $2.71, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-0.46 | $-0.49 – $-0.43 | 4 | n/m |
| 2027-12-31 | $-0.46 | $-0.49 – $-0.43 | 4 | n/m |
| 2028-12-31 | $-0.36 | $-0.45 – $-0.27 | 5 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
